General form of registration statement for all companies including face-amount certificate companies

Stock-based Compensation (Details Narrative) (10-K)

v3.20.2
Stock-based Compensation (Details Narrative) (10-K) - USD ($)
6 Months Ended 12 Months Ended
Dec. 23, 2019
Jun. 20, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Reverse stock split, description 1-for-7 reverse stock split            
Number of stock option granted       129,919 54,915  
Stock option contractual term         5 years 9 months 18 days 9 years 9 months 18 days  
Weighted average exercise price         $ 17.93 $ 20.45
Stock-based compensation expense         $ 510,478 $ 74,063  
Number of option purchase shares     169,329        
Unrecognized compensation expense         $ 1,450,684    
Unvested stock options expected to be recognized over a weighted average period         5 years 9 months 25 days    
Minimum [Member]              
Fair value per share, weighted average         $ 9.88 $ 9.88  
Maximum [Member]              
Fair value per share, weighted average         $ 15.10 $ 15.10  
Non Qualified Stock Options [Member]              
Number of stock option granted           47,772  
Non Qualified Stock Options [Member] | Vested Option One [Member]              
Number of option purchase shares           45,200  
Options vesting period           4 years  
Non Qualified Stock Options [Member] | Vested Option Two [Member]              
Number of option purchase shares           2,572  
Options vesting period           1 year  
Employees [Member]              
Number of stock option granted   129,919          
Stock option contractual term   5 years          
Weighted average exercise price   $ 16.80          
Employees [Member] | Performance Shares [Member]              
Number of stock option granted   64,771          
Employees [Member] | Tranche One [Member] | Service Vesting [Member]              
Number of stock option granted   65,148          
Stock option contractual term   3 years          
Employees [Member] | Tranche One [Member] | In-license a new or additional drug [Member]              
Number of stock option granted   12,958          
Employees [Member] | Tranche Two [Member] | Phase 2a trial for PCS-499 Complete [Member]              
Number of stock option granted   12,958          
Employees [Member] | Tranche Three [Member] | Up-List From The OCTQB [Member]              
Number of stock option granted   38,855          
Employees and Non-Employees [Member]              
Number of stock option granted       129,919   54,915  
Omnibus Plan [Member]              
Number of shares available for issuance 500,000            
Reverse stock split, description one for seven reverse stock split            
2011 Plan [Member]              
Number of option purchase shares           7,143